title: A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.
abstract: The 52-week Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) investigated the gastrointestinal and cardiovascular safety profile of lumiracoxib 400 mg once daily compared with 2 traditional nonsteroidal anti-inflammatory drugs (NSAIDs): ibuprofen 800 mg 3 times daily and naproxen 500 mg twice daily. Data from TARGET were analyzed to examine the effect of lumiracoxib compared with ibuprofen and naproxen on blood pressure (BP), incidence of de novo and aggravated hypertension, prespecified edema events, and congestive heart failure. Lumiracoxib resulted in smaller changes in BP as early as week 4. Least-squares mean change from baseline at week 4 for systolic BP was +0.57 mm Hg with lumiracoxib compared with +3.14 mm Hg with ibuprofen (P<.0001) and +0.43 with lumiracoxib compared with +1.80 mm Hg with naproxen (P<.0001). In conclusion, the use of lumiracoxib and traditional NSAIDs results in differing BP changes; these might be of clinical relevance.
authors.affiliation: Clinical Trials Unit, Mount Sinai Cardiovascular Institute, New York, NY 10029, USA. michael.farkouh@mssm.edu
authors.forename: Michael E
authors.initials: ME
authors.lastname: Farkouh
authors.forename: Freek W A
authors.initials: FW
authors.lastname: Verheugt
authors.forename: Sean
authors.initials: S
authors.lastname: Ruland
authors.forename: Howard
authors.initials: H
authors.lastname: Kirshner
authors.forename: Raban
authors.initials: R
authors.lastname: Jeger
authors.forename: Xavier
authors.initials: X
authors.lastname: Gitton
authors.forename: Gerhard
authors.initials: G
authors.lastname: Krammer
authors.forename: Kirstin
authors.initials: K
authors.lastname: Stricker
authors.forename: Peter
authors.initials: P
authors.lastname: Sallstig
authors.forename: Bernhard
authors.initials: B
authors.lastname: Mellein
authors.forename: Patrice
authors.initials: P
authors.lastname: Matchaba
authors.forename: James H
authors.initials: JH
authors.lastname: Chesebro
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D003404:Creatinine / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004008:Diclofenac / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000008:administration & dosage / Q000494:pharmacology*; D010147:Pain Measurement
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D004008:Diclofenac; D009288:Naproxen; D003404:Creatinine; C473384:lumiracoxib; D007052:Ibuprofen
references.citation: Clin Pharmacokinet. 2004;43(7):467-78
references.pmid: 15139795
references.citation: Scand J Rheumatol. 2004;33(1):1-6
references.pmid: 15124935
references.citation: Am J Ther. 2001 Mar-Apr;8(2):85-95
references.pmid: 11304662
references.citation: Clin J Pain. 2005 Mar-Apr;21(2):147-53
references.pmid: 15722808
references.citation: Am J Cardiol. 2002 Nov 1;90(9):959-63
references.pmid: 12398962
references.citation: Clin Ther. 2005 Jan;27(1):64-77
references.pmid: 15763607
references.citation: Clin Pharmacol Ther. 2002 Jul;72(1):50-61
references.pmid: 12152004
references.citation: Lancet. 2004 Aug 21-27;364(9435):665-74
references.pmid: 15325831
references.citation: Expert Opin Drug Saf. 2006 Jan;5(1):83-94
references.pmid: 16370958
references.citation: J Rheumatol. 2003 Apr;30(4):714-9
references.pmid: 12672188
references.citation: J Hypertens Suppl. 2002 Sep;20(6):S3-9
references.pmid: 12683421
references.citation: Arch Intern Med. 1993 Feb 22;153(4):477-84
references.pmid: 8435027
references.citation: Eur Heart J. 2007 Jun;28(12):1462-536
references.pmid: 17562668
references.citation: Curr Med Res Opin. 2005 Apr;21(4):517-26
references.pmid: 15899100
references.citation: Aliment Pharmacol Ther. 2004 Jul 1;20(1):51-63
references.pmid: 15225171
references.citation: Am J Nephrol. 2001 Jan-Feb;21(1):1-15
references.pmid: 11275626
references.citation: Arch Intern Med. 2005 Mar 14;165(5):490-6
references.pmid: 15710786
references.citation: Ann Intern Med. 1994 Aug 15;121(4):289-300
references.pmid: 8037411
references.citation: Bull World Health Organ. 2003;81(9):646-56
references.pmid: 14710506
references.citation: Am J Manag Care. 2002 Oct;8(15 Suppl):S383-91
references.pmid: 12416788
references.citation: Expert Rev Clin Immunol. 2005 May;1(1):37-45
references.pmid: 20477653
references.citation: Lancet. 2004 Aug 21-27;364(9435):675-84
references.pmid: 15325832
references.citation: Am J Hypertens. 2000 Nov;13(11):1161-7
references.pmid: 11078175